Physician

Joseph Reece Jones, M.D.

According to 2025 Medicare claims, Joseph Jones, M.D. (NPI: 1316092109) practices hematology/oncology in the Daphne-Fairhope-Foley, AL market, with the plurality of this provider's patient population coming from Baldwin, AL. This provider's primary affiliated billing organization is SOUTHERN CANCER CENTER, PC (NPI: 1578629556; TIN: 208097639) and primary practice location at 36535-2229.

Jones' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 840 traditional Medicare patients, billed 229,283 HCPCS/CPT codes, and received $3,259,458 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 4,360 prescription claims across 583 beneficiaries totaling $9,777,255 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 61 claims. Open Payments data shows 153 records totaling $2,994. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,307,885 to $9,777,255. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,621 to $413.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	779	212,435	$3,109,423
2016	820	270,875	$2,996,146
2017	849	285,230	$3,630,405
2018	899	211,072	$3,186,480
2019	810	231,495	$3,412,257
2020	742	209,901	$3,667,896
2021	715	211,200	$3,932,418
2022	772	185,869	$3,992,639
2023	782	177,862	$3,517,092
2024	840	229,283	$3,259,458

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	316	1,632	$1,307,885
2016	346	1,697	$2,070,259
2017	388	2,112	$3,824,962
2018	411	2,456	$5,700,116
2019	413	2,406	$5,036,766
2020	425	2,561	$5,798,740
2021	458	2,778	$7,479,667
2022	463	2,872	$7,299,252
2023	494	3,387	$7,560,968
2024	583	4,360	$9,777,255

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	103	$85,677
2016	N/R	176	$104,086
2017	N/R	141	$63,192
2018	N/R	104	$35,086
2019	N/R	88	$4,674
2020	N/R	78	$4,237
2021	N/R	82	$4,303
2022	N/R	85	$3,938
2023	N/R	72	$3,433
2024	N/R	61	$3,314

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	383	689	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	429	808	$12
80053	Blood test, comprehensive group of blood chemicals	415	1,103	$10
36415	Insertion of needle into vein for collection of blood sample	486	1,605	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	440	1,528	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	142	3,740	$1,746,715
Imbruvica	Ibrutinib	46	1,288	$739,222
Cabometyx	Cabozantinib S-Malate	29	870	$702,195
Tasigna	Nilotinib Hcl	35	980	$636,178
Calquence	Acalabrutinib Maleate	37	1,110	$560,457

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4385	Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each	N	N/R	13	$1,308
A4414	Ostomy skin barrier, with flange (solid, flexible or accordion), without built-in convexity, 4 x 4 inches or smaller, each	N	N/R	11	$1,110
A4425	Ostomy pouch, drainable; for use on barrier with non-locking flange, with filter (2 piece system), each	N	N/R	11	$727
A4367	Ostomy belt, each	N	N/R	13	$85
A4456	Adhesive remover, wipes, any type, each	N	N/R	13	$84

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	153	$2,994	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph Reece Jones, M.D.?

Tedicare shows public-source Medicare data for Joseph Reece Jones, M.D. (NPI 1316092109), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph Reece Jones, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph Reece Jones, M.D.?

Joseph Reece Jones, M.D. is linked to SOUTHERN CANCER CENTER, PC (billing NPI 1578629556) in the available physician profile data.

Does Joseph Reece Jones, M.D. have Open Payments data?

Joseph Reece Jones, M.D. has 153 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.